The mice model market is expected to grow from US$ 1,705.70 million in 2022 to US$ 2,340.90 million by 2028; it is estimated to grow at a CAGR of 5.4% from 2022 to 2028.
Scientists have used animals to model human diseases for over a hundred years. Mice are particularly useful for this because they share many of the same biological traits as humans and have over 80 percent identical genetic components to humans. A mice model is a laboratory mouse used to study some aspect of human physiology or disease. Various model organisms are used in this regard, but mice are particularly useful because they share mammalian traits with humans and suffer from many of the same diseases. Many mice models have been created to target specific human diseases using selective breeding and genetic engineering. The use of mice models in disease research and research programs has contributed to significant medical breakthroughs. Mice are the model of choice, not only because they are strikingly similar to humans at the genomic level but also because the disease pathophysiology in mice is similar to humans. Mice are an inexpensive and efficient tool to speed up research and drug testing. These features provide researchers with a powerful tool for understanding the mechanisms of human disease and for testing novel drug therapies.
Download sample PDF Copy at: https://www.theinsightpartners.com/sample/TIPRE00022453/
Charles River Laboratories; The Jackson Laboratory; Taconic Biosciences, Inc; TRANS GENIC INC.; GenOway S.A.; Envigo; Janvier Labs; Ozgene Pty Ltd.; Crown Bioscience Inc.; and Harbour BioMed are among the leading companies operating in mice model market.
The use of genetically defined inbred mouse strains, humanized mice, and gene knockout mice has enabled the research community to study the process of the way pathogens cause diseases, the role of specific host genes in controlling or promoting disease, and potential targets for prevention or identification of treatment for a variety of infectious agents. With the emergence of new infectious diseases, the animal model has become a vital tool for studying disease mechanisms and developing therapeutics. Mice with xenografted human immune systems have been used to study the pathogenesis of various infectious agents, including Plasmodium falciparum (malaria), Mycobacterium tuberculosis, dengue virus, and influenza virus. These models have been beneficial for studying HIV, including analyzing viral and host factors that promote viral replication, HIV interactions with the host’s immune response, and as platforms for testing therapeutic approaches to control or cure HIV infection. Mice models are an essential resource for studying the mechanisms underlying infectious disease pathogenesis and as platforms for testing potential vaccines and therapies. Mice models are necessary for learning about infections from many human pathogens.
Based on type, the mice model market is categorized into inbred mice, outbred mice, genetically engineered mice, hybrid mice, surgically modified mice, and spontaneous mutant mice. The inbred mice segment is expected to account for the largest share of the market in 2022. However, the genetically engineered mice segment is expected to register the highest CAGR during the forecast period.
Inquiry Before Buying at: https://www.theinsightpartners.com/inquiry/TIPRE00022453/
Below are the major growth strategies undertaken by the players operating in the global mice model market:
In June-2022 – Taconic Biosciences – The company is advancing carcinogenicity testing with an initiative that combines the rasH2 model with genomic technologies—aiming to enable test results that are available earlier in the process and more predictive of human outcomes.
In April-2022 – Taconic Biosciences – Taconic and LifeCanvas are collaborating to investigate how the disease develops and progresses, using advanced 3D histology with two Taconic mouse models used to study Alzheimer’s disease.
In February-2022 – February-2022 – The company has completed the development of exon humanized mice for research on new coronavirus infection (COVID-19). In the future, by providing the same mouse, the company will contribute to elucidation of the infection of COVID-19 and research on infectious disease control at public research institutes.
In September-2021 – Envigo – Envigo RMS Holding Corp. collaborated with Biocytogen. The two companies are committed to supporting research applications of the triple immunodeficient B-NDG mouse. Envigo is the exclusive provider of B-NDG mice in the United States, Europe, and certain Asia-Pacific regions. This mouse model is highly immunodeficient and capable of supporting human immune cell transplantation. The model is widely used in research and drug discovery in many fields including oncology, immuno-oncology, infectious disease, and stem cell biology.
Purchase a Copy of this Report: https://www.theinsightpartners.com/buy/TIPRE00022453/
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi